CSF Tau and P-Tau levels were strongly associated with LF1, LF2, and LF3, while Aβ1-42 was the main contributor to variance among the CSF AD biomarkers to LF4 and LF5 indicating that these latter LFs were associated with amyloid pathology and the former with tau pathology and neurodegeneration. This evidence concerns the gene MAPT and Alzheimer disease.